Press Release: Novartis radioligand therapy -2-

11. Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In:

Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical

Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Michael Meo +1 862 274 5414

Anja von Treskow +41 79 392 9697 Marlena Abdinoor +1 617 335 9525

Anna Schäfers +41 79 801 7267

Switzerland +41 79 619 2035

Satoshi Sugimoto

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

April 23, 2024 13:42 ET (17:42 GMT)